Dr. Jung is currently a principal research scientist at Synthetic Biology and Bioengineering Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), since 1991, in Korea. Based on the bacterial cell surface display he has developed and other innovative protein expression platforms, he found a startup with his colleagues and the company is currently growing in the market. He had also led the technology licensing office in KRIBB from 2008 to 2014 to bridge the gap between the research laboratory and the real world applications of microorganisms. He has been focusing on business development in the field of synthetic biology and metabolic engineering. He is interested in bacterial and yeast probiotics as a therapeutic microorganism and developing a new microbiome for human healthcare treatment. As of October 2018, he published 34 scientific articles, 27 patents, and gave over 80 scientific presentations at the international conferences and the invited seminars.